

SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced that the company will participate at the BIO-Europe Spring meeting on March 23-25, 2026, in Lisbon, Portugal. The event provides a strategic platform to advance discussions with potential pharmaceutical partners.

SynAct Pharma will participate in meetings throughout the week. Thomas Jonassen, CSO, will do an oral company presentation on March 23, 2026, at 16:30-16:45 GMT at the Theatre B company presentation stage.

"BIO-Europe Spring is one of the major partnering events leading up to our expected Phase 2B ADVANCE study topline results on resomelagon in rheumatoid arthritis readout in Q2. We are clearly positioning resomelagon as add-on therapy to methotrexate in newly diagnosed rheumatoid arthritis patients with high disease activity and systemic inflammation, which is where we have seen the most consistent clinical signals. We strongly believe this differentiated approach will expand the current available options for patients to obtain clinical results without adding further risk from immune suppression. We are looking forward to updating companies in the immune disease field about our technology and advance discussions for collaboration," said Mads Bjerregaard, Chief Business Officer of SynAct Pharma.

BIO-Europe Spring 2026 is the premier event for life science with delegates from biotech, medtech, finance and research sectors.

To book a meeting with SynAct Pharma, please connect with the team via the respective event partnering platform.

For further information, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

Attachments

[SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25](#)